Silexion Therapeutics Ltd.(SLXN)Earnings, Financials & Key Ratios
SLXN•NASDAQ
$0.52
$2M mkt cap·Price updated May 7, 2026
AboutSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA-$12M+7.4%
- Net Income-$12M+27.6%
- EPS (Diluted)-8.96-239.4%
- ROE-457.63%
- Debt/Equity0.18
SLXN Key Insights
Silexion Therapeutics Ltd. (SLXN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 78.7% through buybacks
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SLXN Price & Volume
Silexion Therapeutics Ltd. (SLXN) stock price & volume — 10-year historical chart
Loading chart...
SLXN Growth Metrics
Silexion Therapeutics Ltd. (SLXN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM309.47%
Return on Capital
10 Years-325.15%
5 Years-351.01%
3 Years-582.37%
Last Year-612.69%
SLXN Peer Comparison
Silexion Therapeutics Ltd. (SLXN) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 IONS | 12.56B | 76.02 | -31.94 | 33.87% | -30.87% | -58.57% | 5.35 | |
 REGN | 73.68B | 709.10 | 17.10 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MRNA | 19.25B | 48.54 | -6.69 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare SLXN vs Peers
Silexion Therapeutics Ltd. (SLXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLXN Income Statement
Silexion Therapeutics Ltd. (SLXN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 14K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -14K▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 195.86K | 943.93K | 3.86M | 4.68M | 12.57M | 11.63M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 195.86K | 943.93K | 577K | 928K | 6.73M | 4.49M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 0 | 0 | 3.23M | 3.71M | 5.82M | 7.14M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 57K | 45K | 25K | 0 |
| Operating Income | -195.86K▲ 0% | -943.93K▼ 381.9% | -3.86M▼ 308.9% | -4.68M▼ 21.3% | -12.57M▼ 168.6% | -11.63M▲ 7.5% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -381.94% | -308.93% | -21.27% | -168.55% | 7.47% |
| EBITDA | -195.86K | -755K | -3.8M | -4.64M | -12.55M | -11.62M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -285.48% | -403.71% | -21.9% | -170.62% | 7.4% |
| D&A (Non-Cash Add-back) | 0 | 0 | 57K | 45K | 25K | 14K |
| EBIT | -195.86K | -755K | -3.86M | -4.68M | -16.5M | -11.63M |
| Net Interest Income | 0 | 6.37K | 29K | 144K | -51K | 142K |
| Interest Income | 0 | 6.37K | 114K | 153K | 1K | 142K |
| Interest Expense | 0 | 0 | 85K | 9K | 52K | 0 |
| Other Income/Expense | 0 | 188.72K | 396K | -395K | -3.94M | -277K |
| Pretax Income | -195.86K▲ 0% | -755.22K▼ 285.6% | -3.46M▼ 358.7% | -5.08M▼ 46.5% | -16.51M▼ 225.2% | -11.91M▲ 27.9% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 24K | 32K | 10K | 3K |
| Effective Tax Rate % | 0% | 0% | -0.69% | -0.63% | -0.06% | -0.03% |
| Net Income | -195.86K▲ 0% | -755.22K▼ 285.6% | -3.21M▼ 325.7% | -4.94M▼ 53.7% | -16.44M▼ 232.7% | -11.91M▲ 27.6% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -285.59% | -325.7% | -53.72% | -232.72% | 27.56% |
| Net Income (Continuing) | -195.86K | -755.22K | -3.49M | -5.11M | -16.52M | -11.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.05▼ 284.9% | 0.03▲ 176.2% | -4.42▼ 12764.8% | -2.64▲ 40.3% | -8.96▼ 239.4% |
| EPS Growth % | - | -284.87% | 176.2% | -12764.76% | 40.27% | -239.39% |
| EPS (Basic) | -0.01 | -0.05 | 0.03 | -4.42 | -2.64 | -8.96 |
| Diluted Shares Outstanding | 16.51M | 16.51M | 16.73M | 1.12M | 6.24M | 1.33M |
| Basic Shares Outstanding | 16.51M | 16.51M | 16.73M | 1.12M | 6.24M | 1.33M |
| Dividend Payout Ratio | - | - | - | - | - | - |
SLXN Balance Sheet
Silexion Therapeutics Ltd. (SLXN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 51.7K | 407.8K | 8.84M | 4.98M | 2.25M | 6.64M |
| Cash & Short-Term Investments | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M | 5.99M |
| Cash Only | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M | 5.99M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 67K | 49K | 97K | 646K |
| Total Non-Current Assets | 77.7K | 115.01M | 494K | 277K | 613K | 578K |
| Property, Plant & Equipment | 0 | 0 | 464K | 247K | 560K | 437K |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 115.01M | 0 | 0 | 0 | 57K |
| Other Non-Current Assets | 77.7K | 0 | 30K | 30K | 53K | 84K |
| Total Assets | 129.4K▲ 0% | 115.41M▲ 89092.5% | 9.33M▼ 91.9% | 5.26M▼ 43.7% | 2.86M▼ 45.5% | 7.21M▲ 152.0% |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | 89092.47% | -91.91% | -43.68% | -45.53% | 152.01% |
| Total Current Liabilities | 29.4K | 348.58K | 1.61M | 2.2M | 3.52M | 2.76M |
| Accounts Payable | 0 | 0 | 240K | 319K | 929K | 787K |
| Days Payables Outstanding | - | - | - | - | - | 20.52K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1M | 182K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 29.4K | 348.58K | 256K | 407K | 644K | 1.74M |
| Current Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x | 2.41x |
| Quick Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x | 2.41x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 269.99K | 160.34K | 14.8M | 15.12M | 3.33M | 1.85M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 2.96M | 286K |
| Capital Lease Obligations | 0 | 0 | 156K | 59K | 368K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 269.99K | 160.34K | 14.65M | 15.06M | 0 | 1.57M |
| Total Liabilities | 299.39K | 508.92K | 16.41M | 17.31M | 6.85M | 4.61M |
| Total Debt | 0 | 0 | 271K | 171K | 4.49M | 468K |
| Net Debt | -51.7K | -38.94K | -7.99M | -4.42M | 3.3M | -5.52M |
| Debt / Equity | - | - | - | - | - | 0.18x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | -45.41x | -520.11x | -241.75x | - |
| Total Equity | -169.99K▲ 0% | 114.91M▲ 67695.3% | -7.08M▼ 106.2% | -12.06M▼ 70.3% | -3.99M▲ 66.9% | 2.6M▲ 165.3% |
| Equity Growth % | - | 67695.3% | -106.16% | -70.31% | 66.91% | 165.25% |
| Book Value per Share | -0.01 | 6.96 | -0.42 | -10.79 | -0.64 | 1.96 |
| Total Shareholders' Equity | -169.99K | 114.91M | -10.66M | -15.48M | -3.99M | 2.6M |
| Common Stock | 298 | 115M | 1K | 1K | 2K | 42K |
| Retained Earnings | -195.86K | -951.08K | -21.87M | -26.81M | -43.25M | -55.17M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 | 0 |
SLXN Cash Flow Statement
Silexion Therapeutics Ltd. (SLXN) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -75K | -1.41M | -3.33M | -4.53M | -8.4M | -10.82M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -1776.31% | -136.99% | -35.8% | -85.38% | -28.86% |
| Net Income | -195.86K | -755.22K | -3.49M | -5.11M | -16.52M | -11.91M |
| Depreciation & Amortization | 0 | 0 | 57K | 45K | 25K | 14K |
| Stock-Based Compensation | 0 | 0 | 125K | 130K | 5.86M | 134K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -182.34K | -268K | 317K | 3.82M | 344K |
| Working Capital Changes | 120.86K | -469.68K | 239K | 87K | -1.58M | 601K |
| Change in Receivables | 0 | 0 | -40K | 18K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -38K | 79K | 610K | -40K |
| Cash from Investing | 0 | 0 | -524K | 573K | -22K | -14K |
| Capital Expenditures | 0 | 0 | -40K | -12K | -22K | -9K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 78K | 0 | 0 |
| Cash from Financing | 126.7K | 116.4M | 2.75M | 522K | 5.1M | 15.64M |
| Debt Issued (Net) | 149.99K | 150.01K | 0 | 0 | -250K | -696K |
| Equity Issued (Net) | -23.29K | 1000K | 1000K | 522K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -2.55M | 3K | 0 | 2.3M | 0 |
| Net Change in Cash | 51.7K▲ 0% | -12.76K▼ 124.7% | -1.77M▼ 13806.1% | -3.66M▼ 106.5% | -3.38M▲ 7.9% | 4.8M▲ 242.4% |
| Free Cash Flow | -75K▲ 0% | -1.41M▼ 1776.3% | -3.38M▼ 139.8% | -4.54M▼ 34.5% | -8.42M▼ 85.4% | -10.83M▼ 28.6% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -1776.32% | -139.83% | -34.55% | -85.38% | -28.63% |
| FCF per Share | -0.00 | -0.09 | -0.20 | -4.06 | -1.35 | -8.14 |
| FCF Conversion (FCF/Net Income) | 0.38x | 1.86x | 1.04x | 0.92x | 0.51x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
SLXN Key Ratios
Silexion Therapeutics Ltd. (SLXN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1.32% | -5.96% | - | - | -457.63% |
| Return on Invested Capital (ROIC) | - | -1.23% | -5.8% | - | - | - |
| Debt / Equity | - | - | - | - | - | 0.18x |
| Interest Coverage | - | - | -45.41x | -520.11x | -241.75x | - |
| FCF Conversion | 0.38x | 1.86x | 1.04x | 0.92x | 0.51x | 0.91x |
SLXN Frequently Asked Questions
Silexion Therapeutics Ltd. (SLXN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Silexion Therapeutics Ltd. (SLXN) grew revenue by 0.0% over the past year. Growth has been modest.
Silexion Therapeutics Ltd. (SLXN) reported a net loss of $11.9M for fiscal year 2025.
Dividend & Returns
Silexion Therapeutics Ltd. (SLXN) has a return on equity (ROE) of -457.6%. Negative ROE indicates the company is unprofitable.
Silexion Therapeutics Ltd. (SLXN) had negative free cash flow of $10.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More SLXN
Silexion Therapeutics Ltd. (SLXN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates